چاپ صفحه |  صفحه نخست سامانه |  چکیده مقاله |  نویسندگان |  دانلود مقاله | دانشگاه علوم پزشکی تبریز |
| Introduction: Statins are one of the most widely used therapies in different groups of patients not only because of cholesterol-lowering properties but also due to their non-lipid related mechanisms. However, the effects of atorvastatin on inflammatory and coagulation markers in type 2 diabetic patients are not well examined. Objectives: To evaluate, the effects of two different doses of atorvastatin on lipid profile, inflammatory coagulation markers, and liver enzymes in type 2 diabetic patients. Patients and Methods: In a randomized double-blinded controlled trial, 150 diabetic patients were randomly assigned to get atorvastatin 10 mg/d (n = 74) or 40 mg/d (n = 76) for 12 weeks. The concentration of biomarkers was determined both at the onset of the study as well as at the completing time of the intervention. Results: Significant differences between the mean levels of lipid profiles, fibrinogen, interleukin-1 (IL-1) and IL-6 were observed between two groups after three months treatment with atorvastatin 10 and 40 mg/d (P<0.05). Furthermore, significant improvement in all blood values after atorvastatin 40 mg/d ingestion was observed (P<0.05) except for homocysteine and creatine phosphokinase (CPK) levels (P>0.05). Conclusion: Atorvastatin therapy especially with higher dose was associated with inflammation and coagulation parameters improvement in diabetic individuals. Trial Registration: Registration of randomized double-blinded clinical trial has been approved in Iranian registry of clinical trial (identifier: IRCT201502226710N5; http://www.irct.ir/trial/7136). |
| نویسنده | نفر چندم مقاله |
|---|---|
| میترا نیافر | اول |
| امیر بهرامی | دوم |
| ندا لطفی یقین | سوم |
| فرزاد نجفی پور | چهارم |
| ناصر آقا محمد زاده | پنجم |
| وحیده صدرا | ششم |
| نام فایل | تاریخ درج فایل | اندازه فایل | دانلود |
|---|---|---|---|
| ipp-5-e01.pdf | 1398/04/16 | 373298 | دانلود |
